Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:HALO

Halozyme Therapeutics Q3 2026 Earnings Date & Estimates

Halozyme Therapeutics logo
$125.63 +1.09 (+0.88%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$125.64 +0.01 (+0.01%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Halozyme Therapeutics in Q3 2026

Halozyme Therapeutics is expected to post earnings of $2.30 per share on revenue of $490.85 million. In the same quarter a year earlier Halozyme Therapeutics reported $1.72 per share on revenue of $354.26 million. Halozyme Therapeutics last reported on August 6, 2026, posting $2.28 per share and beating the $1.79 consensus estimate. Halozyme Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.30
Expected Revenue
$490.85 million
Prior-Year EPS
$1.72
Prior-Year Revenue
$354.26 million
Expected EPS Growth
+33.7%
Expected Revenue Growth
+38.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.28 (Beat by +$0.49)
Last Quarter Revenue
$481.00 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Halozyme Therapeutics Q3 2026 Earnings FAQ

Halozyme Therapeutics (NASDAQ:HALO) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Halozyme Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Halozyme Therapeutics to post earnings of $2.30 per share for Q3 2026.

The consensus revenue estimate for Halozyme Therapeutics is $490.85 million for Q3 2026.

Halozyme Therapeutics Earnings Headlines

How Halozyme, up nearly 90% this year, is rivaling Merck and hitting new highs
October 24 at 10:33 AM  |  msn.comhttps://www.msn.com/en-us/news/other/how-halozyme-up-nearly-90-this-year-is-rivaling-merck-and-hitting-new-highs/ar-AA2fV9Ol
How Halozyme, up 80% this year, is rivaling Merck and hitting new highs
October 23 at 6:16 PM  |  msn.comhttps://www.msn.com/en-us/news/other/how-halozyme-up-80-this-year-is-rivaling-merck-and-hitting-new-highs/ar-AA2fV9Ol
SpaceX is worth trillions. This one's $14.
It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork, and anyone with a brokerage account can buy shares for about 14 dollars. When SpaceX went public, roughly 4,400 employees became what Dylan Jovine calls the first wave of Space Millionaires. He believes a second wave begins December 8th, when the lockup ends.tc pixel
October 24 at 1:00 AM  |  Behind the Markets (Ad)
Halozyme to Report Third Quarter 2026 Financial and Operating Results
October 22 at 8:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/halozyme-to-report-third-quarter-2026-financial-and-operating-results-302916279.html
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High - What's Next?
October 21 at 4:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31142322
H.C. Wainwright Reaffirms Their Buy Rating on Halozyme (HALO)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8097469/h-c-wainwright-reaffirms-their-buy-rating-on-halozyme-halo/
See More Halozyme Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Halozyme Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your email.

About Halozyme Therapeutics

Halozyme Therapeutics (NASDAQ:HALO) is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products. ENHANZE-enabled medicines include subcutaneous formulations such as DARZALEX FASPRO for multiple myeloma, PHESGO for certain forms of breast cancer, and VYVGART HYTRULO for generalized myasthenia gravis. The company also develops and commercializes drug-delivery products and injection technologies through its proprietary business.

Founded in 1998 and headquartered in San Diego, California, Halozyme serves international markets primarily through collaborations with global pharmaceutical companies. Its partners are responsible for developing, obtaining regulatory approval for, and commercializing many products that incorporate Halozyme’s technologies, allowing the company’s drug-delivery platforms to support treatments across multiple therapeutic areas and geographies.

View Halozyme Therapeutics Profile
Earnings Tools